LI
Lincoln Pharmaceuticals Ltd (LINCOLN)
₹573.30
Mkt cap
₹1,212 Cr
P/E ratio
12.60
P/B
1.52
Div yield
0.30%
ROE
12.30%
ROCE
16.30%
EPS (TTM)
₹45.50
Book value
₹378
52W range
440–770
Sector
Healthcare
Price history
Previous close
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
NSE LINCOLNBSE 531633
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−25.55% from high₹573
₹440+30.30% from low₹770
Current
₹573.30
Prev close
₹565.05
Day
+1.46%
Price performance
1D
+1.46%
1W
−1.47%
1M
−7.93%
3M
−7.48%
6M
−5.22%
1Y
+6.70%
YTD
+15.32%
Financials
Revenue, profit & margin
P/E ratio
12.6×
LINCOLN is 64% below the sector median of 34.6×
LINCOLN12.6×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 | |
| Expenses | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 | |
| Operating Profit | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 | |
| OPM % | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% | |
| Other Income | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | |
| Profit before tax | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 | |
| Tax % | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% | |
| Net Profit | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 | |
| EPS in Rs | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +4.50% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26 |
| Earnings day | +4.50% |
| +1 day | +3.47% |
| +5 days | +5.02% |
| +15 days | +5.03% |
| +30 days | −0.31% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202649.78%Promoter
Promoters49.78%
FIIs4.60%0.60
DIIs0.27%0.81
Public45.36%1.42
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Lincoln Pharma. | ₹604.85 | 12.56 | 1,212 | 0.30% | 36 | +30.89% | 177 | +15.06% | 16.27% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts36
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep - Newspaper Publication for Notice of 32nd Annual General Meeting.Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company. 5 Sep - 32nd AGM on 30 Sep 2026 at 11:00 AM; annual report 2025-26 shared with shareholders.Reg. 34 (1) Annual Report. 5 SepNotice Of 32Nd Annual General Meeting Of The Company. 5 SepIntimation Of Book Closure And Record Date For The Purpose Of 32Nd Annual General Meeting And Final Dividend For The Financial Year 2025-26. 29 Aug - AGM on Sep 30, 2026; record date Sep 11, book closure Sep 12-30; final dividend 18%.